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Therapeutic targetThe HIV-1 protein Tat is a critical regulator of viral transcription and has also been implicated as a mediator of
HIV-1 induced neurotoxicity. Here using a high throughput screening assay, we identiﬁed the GSK-3 inhibitor
6BIO, as a Tat-dependent HIV-1 transcriptional inhibitor. Its ability to inhibit HIV-1 transcription was
conﬁrmed in TZM-bl cells, with an IC50 of 40 nM. Through screening 6BIO derivatives, we identiﬁed 6BIOder,
which has a lower IC50 of 4 nM in primarymacrophages and 0.5 nM in astrocytes infected with HIV-1. 6BIOder
displayed an IC50 value of 0.03 nM through in vitro GSK-3β kinase inhibition assays. Finally, we demonstrated
6BIO and 6BIOder have neuroprotective effects on Tat induced cell death in rat mixed hippocampal cultures.
Therefore 6BIO and its derivatives are unique compounds which, due to their complex mechanisms of action,
are able to inhibit HIV-1 transcription as well as to protect against Tat induced neurotoxicity.r and Microbiology, National
n University, 10900 University
703 993 4280.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Although current antiretroviral therapy has had a major impact on
prolonging the life span of HIV-1 infected individuals it also has
important limitations. Most of these therapies prevent viral entry into
the cells or formation of proviral DNA. However, once the proviral
DNA is integrated into the chromosome, the protease inhibitors are
the only class of drugs available that prevents the formation of
infectious viral particles. These compounds do not prevent the
formation of the early viral proteins such as Tat. The HIV-1 Tat
protein is a critical regulator of HIV replication and can be released
extracellularly where it may have a multitude of effects. This is
particularly important within the brain, where the virus enters early
in the course of infection and establishes reservoirs in glial cells.
Extracellular Tat is a potent neurotoxin and may be an important
mediator of neuronal dysfunction associated with HIV-1-associatedneurocognitive disease (HAND) (Magnuson et al., 1995; Maragos
et al., 2003; Sabatier et al., 1991; Weeks et al., 1995). Recent studies
suggest that despite excellent control of HIV replication in the
periphery, nearly 50–70% of individuals develop neurocognitive
impairment. Hence approaches to prevent the effects of HIV
replication in the brain are critically necessary.
Elongation of HIV-1 transcripts is dependent on the association of
HIV-1 Tat with the nascent RNA stemloop structure of the transactiva-
tion response element (TAR). This process is accompanied by the
binding of several cellular proteins, in particular the P-TEFb complex
comprising of cyclin T1 or CDK9 to the RNAP II complex associatedwith
theHIV-1 LTR (Fujinaga et al., 1998; Herrmann and Rice, 1995; Laspia et
al., 1989; Nabel and Baltimore, 1987; Peng et al., 1998; Rice and
Mathews, 1988; Sobhian et al., 2010; Wei et al., 1998). This unique
interaction of HIV-1 Tat with TAR it provides an ideal target for
pharmaceutical intervention. In vitro a variety of compounds have been
demonstrated to inhibit HIV-1 replication. Some of these compounds
have been described to speciﬁcally interfere with Tat–TAR interaction.
The Novartis compound CGP 40336A was described to selectively bind
to the AU base pair above the trinucleotide bulge with additional
stacking interactions to the bulge (Hamy et al., 1998). The multicyclic
dyes, Hoechst 33258, DAPI and berenil bind to the cavity created by the
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Edwards and Sigurdsson, 2002; Mestre et al., 1999). Neomycin binds to
theminor groove of the lower helix,whereas argininamidewas found to
bind to the U23–A27–U38 base triple (Aboul-ela et al., 1995; Brodsky
et al., 1998; Brodsky and Williamson, 1997; Faber et al., 2000; Nifosi et
al., 2000). Other compounds inhibit HIV-1 transcription without
interfering with Tat–TAR interaction (K-12, Ro24-7429) (Baba et al.,
1998; Baba et al., 1997; Hsu et al., 1993). However, none of these
compounds have proven clinically useful. Ro24-7429 was even
advanced into early clinical trials (Hsu et al., 1993), but no inhibitory
effect on HIV-1 replication in patients was observed during a Phase I/II
clinical trial, despite sufﬁciently high drug plasma levels and no
development of viral resistance (Haubrich et al., 1995). While some
drug targets, such as the Tat–TAR interaction are clearly deﬁned, the
more recent discoveries that WP631, Temacrazine or CDK inhibitors
(Agbottah et al., 2005; Galons et al., 2010; Guendel et al., 2010;
Kashanchi and Kehn-Hall, 2009; Malumbres et al., 2008; Van Duyne et
al., 2008), would also inhibit HIV-1 transcription hint at the possibility
that there are potential features of HIV-1 transcription that are not
appreciated as drug targets yet.
Tat is released by infected lymphoid (Ensoli et al., 1993) and glial cells
(Tardieu et al., 1992). Both forms of Tat are released (i.e. Tat formed by
the ﬁrst exon only, and that formed by both ﬁrst and second exons)
(Malim and Cullen, 1991) and are cytotoxic to neurons (Magnuson et al.,
1995; Maragos et al., 2003; Sabatier et al., 1991; Weeks et al., 1995). Tat
effects on neurons involve excitotoxic mechanisms, and this is similarly
true for gp120. αv integrin subunit-containing receptors (Barillari et al.,
1993; Etienne-Manneville and Hall, 2001; Noonan and Albini, 2000),
vascular endothelial growth factor-1 receptor (VEGF-1 receptor or ﬂt-1)
(Krum and Rosenstein, 1998), low-density lipoprotein receptor-related
protein (LPR) (Liu et al., 2000), and NMDA receptors (Haughey et al.,
2001) (NMDA receptor activationmay be secondary to GPCR activation)
(HaugheyandMattson, 2002;Nathet al., 1996)haveall beenproposedas
targets for Tat (Noonan and Albini, 2000; Rusnati and Presta, 2002).
Interactionswithexcitatoryaminoacid receptors (HaugheyandMattson,
2002; Magnuson et al., 1995; Nath et al., 1996), with accompanying
increases in Ca2+ and reactive oxygen species (Bonavia et al., 2001;
Kruman et al., 1998; Nath et al., 1996),may be especially detrimental. Tat
injection into the brain (Jones et al., 1998; Philippon et al., 1994; Sabatier
et al., 1991), including the striatum(Bansal et al., 2000) causes gliosis and
inﬁltration of macrophages, production of cytotoxic cytokines, and
chemokines such as MCP-1 (Conant et al., 1998; Weiss et al., 1999).
Intrastriatal Tat injections induce neurodegenerative changes (Aksenov
et al., 2003; Philippon et al., 1994), which precedes peak increases in
macrophages/microglia at 24 hours (Aksenov et al., 2003). Dying
neurons are no longer seen at 7 days following Tat exposure during
peak periods of astrogliosis suggesting the neuronal losses are not
secondary to reactive astroglial changes. There is also evidence from
culture studies that Tat is directly neurotoxic because toxicity occurs in
highly enriched cultures of striatal neurons (Bonavia et al., 2001). Very
brief exposures to Tat can cause neuronal death (Magnuson et al., 1995;
Nath et al., 1999). The core domain of Tat, amino acids 21–40 can induce
cytopathic effects in monocytes and angiogenesis (Boykins et al., 1999).
Here we present data on small chemical molecules that can inhibit
both Tat-dependent transcription and Tat induced neurotoxicity. These
small chemical molecules are inhibitors of GSK-3β, which is known to
have important implications in HAND. We reasoned that signaling
molecules downstreamof Tat thatmay be common to its effects onHIV-
1 replication and neurotoxicity may be important therapeutic targets.
Results
HIV-1 transcriptional inhibitor screening system
We have previously developed an HTS-compatible reporter cell
line in which a stably integrated chronically active HIV-1 derived froma patient isolate drives eGFPexpression controlled by aHIV-1 LTR (CUCY
cells-Jurkat based) (Kempf et al., 2006). eGFP expression thus serves as a
direct and quantitativemarker of HIV-1 expression. By the inclusion of a
second ﬂuorescent protein that can be spectrally separated from GFP
(DsRedExpress) and which is controlled by an activation-independent
promoter (MSCV-LTR), we obtained a reporter cell line inwhichwe can
simultaneously measure the inﬂuence of compounds on HIV-1
transcription (on-target) and general transcription (off-target). By this
means, false positive hits, in which the compound would non-
speciﬁcally inhibit global transcription, could be minimized.
However, the requirement for a BSL2+/BSL3 facility to perform
the actual drug screen is very restrictive and also signiﬁcantly
increases the costs of drug screening. To overcome these limitations,
we had earlier attempted to establish a non-infectious drug screening
system similar to CUCY cells, in which the integrated LTR-eGFP
promoter construct in the parental JLTRG cells would be activated
through stably integrated HIV-1 Tat expression plasmids. However,
initial attempts to obtain high eGFP expressing cells through either
stable transfection or retroviral transduction with Tat expression
vectors failed. For example, retroviral vectors expressing HIV-1 Tat
under the control of the murine leukemia promoter were found to
efﬁciently transduce JLTRG cells, as indicated by the initially high
measurable levels of eGFP expression, but then gradually lost eGFP
expression, probably due to promoter methylation. We solved this
problem by using retroviral vectors that express HIV-1 Tat under the
control of the murine stem cell virus promoter (Swindle et al., 2004).
Through an iterative process of retrovirally transducing JLTRG cells
with the Tat vectors, sorting the transduced cells for high eGFP
expression, supertransducing this eGFP-positive population, etc., we
were able to obtain a cell population that generates a HIV-1 Tat-driven
eGFP ﬂuorescence intensity similar to that observed in CUCY cells
(Fig. 1A). We were then able to transduce these cells with retroviral
vectors expressing high levels of RFP, which similarly as in CUCY cells
can serve as a simultaneously accessible marker for drug toxicities
(Fig. 1B). Final single cell cloning for high eGFP/RFP expressing cells
resulted in the establishment of the clonal TiGR cell line. eGFP and
DsRed expression in TiGR cells is stable. Over 6 months of continuous
culture, we only observed a 10% decrease of eGFP expression at the
population basis. However, at this time-point, a 100% double-positive
cell population can be easily regenerated by cell sorting.
We initially established the ideal per well cell density by titrating
TiGR cells at various cell densities into 384-well plates. The eGFP/RFP
signals increase in a linear manner from a cell density of 5×103 cells/
well, with 2×105 cells (15-fold signal increase over background)
being optimal for cell screening. At this cell density Z′ was deﬁned as
0.89, indicating that the assay is very robust (Fig. 1C). The
experimentally determined Z′ factor is a dimensionless statistical
value designed to reﬂect the dynamic range as well as the variation of
the assay. It calculates as Z′=1−(3σp+3σn)/|μp−μn). With 3σn
representing the standard deviation of the negative control samples,
3σp representing the standard deviation of the positive samples, μn
the mean of the negative control samples and μp the mean of the
positive samples. Z′=1 would be an ideal assay and 1NZ′N0.5 are
considered very good to excellent assays.
We next veriﬁed the TiGR based HTS assay in a small manually
performed1000 compound screen and included someknown inhibitors
of HIV-1 transcription (Ro24-7429, WP631) as controls, which were
efﬁciently detected (80–90% eGFP signal reduction on day 7; data not
shown). As TiGR cells use ﬂuorescence intensities as quantitative
markers for HIV-1 expression and drug toxicities, drug effects can be
assessed intervention free. As such, the assay determines not only the
cumulative inhibition at a deﬁned time point but also the inhibitory/
toxic onset kinetics of a respective compound, which gives additional
insights into the possible drug efﬁciency. Therefore, this assay system
serves as a standardized platform to screen for Tat LTR transcriptional
inhibitors.
Fig. 1. HIV-1 transcriptional inhibitor screening system. Comparison of eGFP (A) and RFP (B) expression in CUCY cells and the TIGR reporter cells used in this application. (C) Z-test
results for TiGR cells. 2×105 TiGR cells were loaded into 48 wells of a 384-well plate and eGFP ﬂuorescence intensity was measured (black circles) compared to eGFP ﬂuorescence of
the parental JLTRG cells (gray squares) loaded into 48 wells of the same plate.
Table 1
Tat-dependent Transcription Inhibitors.
Inhibitor Description and target % Inhibition
at 1 μM
Dactiniomycin Antineoplastic, intercalating agent 98
6BIO Glycogen synthase kinase 3α/β inhibitor 62
Quinine ethyl carbonate Antimalarial 34
Indirubin-3′-oxime CDK inhibitor 25
Epirubicin hydrochloride Antineoplastic 17
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LOPAC-Sigma-Aldrich (1280 compounds) and Spectrum-Micro-
source (2000 compounds) small compound libraries were screened
using the TiGR cells described above to identify novel HIV-1 transcrip-
tion inhibitors. These libraries were chosen as they contain pharmaco-
logically active compounds, known FDA-approved drugs, experimental
bioactives, and pure natural products which provided a wide range of
compounds with potential biological activity. Compounds were diluted
in DMSO and screened at 10 μM for Tat transcriptional inhibition. TiGR
cells were analyzed at days 0, 1, 2, 3, 4 and 7 post drug treatments to
determine the GPF and RFP signals and those compounds that exhibited
greater than 30% inhibition of GFP expression without affecting the RFP
expression were selected for further analysis. We identiﬁed ﬁve
candidates based on these criteria. The top ﬁve candidates that were
identiﬁed through the TiGR cell system were tested in TZM-bl cells,
which contain an integrated LTR-luciferase reporter. As the TZM-bl
system was utilized as our secondary screen, we chose 1 μM as a more
stringent cut-off for selection of our lead candidate. TZM-bl cells were
transfected with Tat followed by compound treatment the next day.
Results shown in Table 1 indicate the %inhibition observed at 1 μM as
compared to the DMSO control. The compound with the greatestinhibition was the chemotherapeutic agent Dactinomycin, which is a
transcriptional inhibitor and anti-proliferation compound (Ho et al.,
2008). Its mechanism of action is non-speciﬁc as it binds to multiple
DNA structures such as GC-rich duplexes, single-stranded forms, or
hairpin forms, as well as interfering with RNA polymerase (Kang and
Park, 2009). Although toxicity was not observed in the TIGR cells, the
above characteristics suggest the limited HIV-1 therapeutic potential
of this compound; therefore we chose not to further pursue Dactino-
mycin. Out of the remaining compounds, the GSK-3 inhibitor 6BIO (6-
bromoindirubin-3′-oxime) (Meijer et al., 2003; Polychronopoulos et al.,
2004) was ranked the secondmost potent LTR transcriptional inhibitor
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inhibits Tat-dependent LTR transcription.
6BIO inhibits HIV-1 transcription without inducing cellular toxicity
The best candidate identiﬁed in our screen, 6BIO, was further
tested using TZM-bl cells to determine its IC50. TZM-bl cells were
transfected with Tat followed by treatment with various concentra-
tions of 6BIO the next day. Luciferase assays performed at 2 days post
6BIO treatment indicated that 6BIO inhibited HIV-1 LTR Tat-
dependent transcription in a dose-dependent manner (Fig. 2A),
with an IC50 of 40 nM. MTT assays were performed to determine the
inﬂuence of 6BIO on cell viability. As can be seen in Fig. 2B, at the
concentrations used in our transcriptional assays, 6BIO did not affect
cell viability. MTT assays were also performed with 6BIO on multiple
other cell types, including uninfected and infected T-cell lines (CEM
and ACH2), uninfected and infected monocytic cell lines (U937 and
U1) and an astrocytoma cell line (U87MG). No cellular toxicity was
observed upon treatment with 6BIO (1 μM) as compared to the DMSO
control (data not shown). These results indicate that 6BIO can inhibit
HIV-1 transcription without inhibiting cellular viability.
To determine whether 6BIO has an effect on HIV-1 replication in
primary cells, we infected activated PBMCs with the dual tropic 89.6
virus and subsequently treated cells with vehicle (DMSO) or various
concentrations of 6BIO (0.1, 0.5, and 1.0 μM). Treatment was
performed only one time. Cells were maintained for 14 days and
supernatants were collected at days 7 and 14 for RT analysis (Fig. 2C).
Results indicate that 1.0 μM of 6BIO inhibited virus replication by
more than 50% after 7 and 14 days. Cells were also collected toFig. 2. 6BIO inhibits HIV-1 transcription and replication without inducing cellular toxicity. (A
6BIO (0.025, 0.05, 0.1, and 1.0 μM). Cells were processed 48 hours post drug treatment for lu
standard deviation. (B) TZM-bl cells were treated with DMSO or 6BIO (0.025, 0.05, 0.1, and
performed in triplicate and samples analyzed at 48 hours. (C) PHA and IL-2 activated PBMCs
performed by following the guidelines of the Centers for Disease Control. Approximately 2.5×
of complete media and plated in a 96well plate at 200 μl/well. 6BIO treatment (0, 0.1, 0.5 and
on days 7 and 14 and stored at−20 °C for RT assay. Treatments were performed in triplicate
described for C. Cells were collected on days 7 and 14, washed 2× with PBS without Ca and
analysis by ﬂow cytometry to determine apoptosis (sub-G1 peak). Triplicate wells were podetermine the inﬂuence of 6BIO treatment on cell viability using PI
staining/FACS analysis. Apoptosis was determined through cell cycle
analysis (sub G1 peak). Uninfected PBMCs displayed low levels of
apoptosis at both days 7 and 14 (Fig. 2D). Infected PBMCs also
demonstrated low levels of apoptosis at day 7. However, at day 14 an
increase in apoptosis was observed in the infected cells probably due
to viral induced cell death as the DMSO control cells were also
beginning to die and due to the fact that BIO treatment was unable to
completely suppress viral replication. Collectively these results
indicate that the IC50 of the 6BIO inhibition is ~0.75 μM in HIV-1
infected PBMCs and that 6BIO can inhibit HIV-1 replication without
inhibiting cellular viability.
Identiﬁcation of a more potent 6BIO analog
Hit2Lead (Hit2Lead.com) was utilized to identify thirty-eight
commercially available 6BIO analogs. These analogs were tested at
1 μM in the TZM-bl cells to test their ability to inhibit Tat-dependent
LTR transcription (Fig. 3A). Many of the analogs actually increased
viral transcription as compared to the DMSO control, especially
compounds 16 and 31 possibly due to removal of inhibitors from the
promoter. In contrast, a few analogs tested displayed LTR transcrip-
tional inhibition with different potencies (compounds 4, 6, 18).
Derivative #6 showed particularly strong inhibition of LTR transcrip-
tion. MTT assays were performed with derivative #6 on multiple cell
lines, including uninfected and infected T-cells (CEM and ACH2),
uninfected and infected monocytes (U937 and U1) and astrocytoma
cells (U87MG). Results indicated that the transcriptional inhibition
was not due to cellular toxicity (Fig. 3B) as very little change in) TZM-bl cells were transfected with 1.0 μg of Tat and treated the next day with DMSO,
ciferase assays. Assays were performed in triplicate and an average value is shown plus
1.0 μM). Cell proliferation/viability was determined by MTT assays. Treatments were
were kept in culture for 2 days prior to infection. Isolation and treatment of PBMCs were
107 PBMCs were infectedwith 89.6 (35,520 RT units). Cells were resuspended in 6.5 ml
1.0 μM)was performed (only once) the day following infection. Samples were collected
and the average plus the standard deviation is displayed. (D) PBMCs were processed as
Mg, resuspended in 70% ethanol, and stained with propidium iodine prior to cell cycle
oled for this analysis.
Fig. 3. 6BIO derivatives inhibit HIV-1 transcription without inducing cellular toxicity. (A) TZM-bl cells were transfected with 1.0 μg of Tat and treated the next day with DMSO, 6BIO,
derivatives 1–38 at 1 μM. Cells were processed 48 hours post drug treatment for luciferase assays. Assays were performed in triplicate and an average value is shown plus standard
deviation. (B) CEM, ACH2, U937, U1, and U87MG cells were treated with DMSO and derivative #6 (1 μM). Cell proliferation/viability was determined byMTT assays. Treatments were
performed in triplicate and samples analyzed at 48 hours. Percent viability is expressed as compared to the DMSO control.
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compared to the DMSO control. Derivative #6 was termed 6BIOder
and selected for follow-up analysis.
Effect of 6BIO analogs on inhibition of HIV-1 in monocytes and
astrocytoma cells
To further test the effect of 6BIOder, we assayed its effect in
primary monocyte/macrophage infection along with the parent 6BIO
drug. Fig. 4A shows the general structure of 6BIO and 6BIOder. Both
compounds are commercially available, however 6BIOder has not
been studied in the context of HAND. Data in Fig. 4B utilized
monocyte/macrophages from a healthy donor infected with HIV-1
dual tropic 89.6 for 7 days. Both 6BIO and 6BIOder were added to the
media during the course of infection (once only). Lane 1 shows
normal replication of HIV-1 as evidenced by RT activity in supernatant
and lane 2 is with DMSO control. Lane 3 used 6BIO (10 nM) and 4–7
utilized 6BIOder (0.1, 1, 10, 100 nM). There was considerable
inhibition with 6BIOder at 10 nM. The IC50 for 6BIOder in these cells
is 4 nM. Next, we performed a similar assay in U87MG cells with
6BIOder at 0.1, 1 and 10 nM (left hand graph). Again, inhibition was
mostly observed at 1 nM with IC50=0.5 nM. Finally, we performed
MTT assays withmonocyte/macrophage from two healthy donors and
U87MG at 10, 100, 1000 and 10,000 nM (lanes 2–5) and observed noapparent toxicity in these cells (Fig. 4C). Collectively, these data
indicate that when searching for 6BIO related compounds to inhibit
HIV-1, wewere able to identify 1 out of 38 compounds that had IC50 of
0.5–4 nM (depending on the cell type) and were not toxic to cells at
10 μM. This is roughly a 3 log difference between HIV-1 inhibitory
activity and possible cell toxicity.
6BIOder does not inhibit cellular gene expression in the absence of Tat
and is speciﬁc to GSK-3β
We next asked whether 6BIOder was inhibitory to genes that
require CDK9/cyclin T. HIV-1 Tat utilizes CDK9/cyclin T for its
activation of transcription. We therefore asked if cellular gene
expression would be sensitive to 6BIOder in treated cells. Results in
Fig. 5A show RT/PCR results of 3 genes that require CDK9/cyclin T for
their transcription. None of these genes showed a dramatic decrease
after 6BIOder treatment in U937 or U87MG cells in the absence of Tat.
Interestingly, we did observe an increase in expression for MCL-1, IL-
8, and cyclin D1 following 6BIOder treatment of U937 cells. Next we
asked if 6BIO or 6BIOder was able to inhibit GSK-3β kinase activity.
U937 cells were treated with 6BIO or 6BIOder, followed by
immunoprecipitation with anti-GSK-3β. The IPed material was
utilized for in vitro kinase assays with glycogen synthase peptide 2
as the substrate. Results in Fig. 5B indicate that BIOder and not 6BIO
Fig. 4. Effect of 6BIO and 6BIOder on HIV-1 replication. (A) Structure of 6BIO: 2-{[[2-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3 ylidene)hydrazino](oxo) acetyl]amino} benzoic acid and
6BIOder: 6-bromo-5-methyl-1H-indole-2,3-dione 3-[(6-bromo-5-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazone]. (B) PMBCs were obtained from the blood of healthy donor
(YW), and puriﬁed by centrifugation through a layer of Lymphocyte Isolation Medium. Cells were resuspended in serum-free RPMI and plated on culture dish for 1 hour at 37 °C.
Non-adherent lymphocytes were removed and the adherent monocytes were cultured in RPMI plus 10% heat-inactivated FBS. Macrophages were further differentiated by incubating
in 10 ng/ml M-CSF for 1 week withmedium change every 2 days. Bothmacrophages and U87MG cells were infected with 89.6 (MOI:1). 6BIO (lane 3, 10 nM) 6BIOder (lanes 4–7: 0.1,
1, 10, 100 nM) were added to cells 6 hours after infection. U87MG cells were treated with 6BIOder at 0.1, 1 and 10 nm (left side of panel B). Samples were collected on day 7 for RT
assay. Treatments were performed in triplicate and the average plus the standard deviation is displayed. (C) MTT assays in two monocyte/macrophage healthy donors and U87MG
were performed after treatment with 6BIOder at 10, 100, 1000 and 10,000 nM (lanes 2–5).
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estimated in vitro IC50 for 6BIOder in these kinase assays for GSK-3β is
0.03 nM. Collectively, these results indicate that 6BIOder is an
effective GSK-3β inhibitor.Fig. 5. 6BIOder does not inhibit cellular gene expression in the absence of Tat and is speciﬁc to
RNA was treated with 0.25 mg/ml DNase I for 1 hour, followed by heat inactivation at 65 °C
cDNA Synthesis kit using oligo-dT reverse primers. Primers for PCR were MCL-1, IL-8, cyclin D
with GSK-3β antibody. The next day complexes were precipitated with A/G beads for 2 ho
reactions were performed with IP material and 200 ng of glycogen synthase peptide 2 (Millip
and subjected to analyzed using Molecular Dynamics Phosphor Imager software.Knockdown of GSK-3β decreases viral transcription in cells
We next asked whether downregulation of GSK-3β in cells could
potentially decrease viral gene expression and/or viral load in infectedGSK-3β. (A) Total RNAwas isolated from cells treated with 6BIOder (1 μM) using Trizol.
for 15 minutes. A total of 1 μg of total RNA was used to generate cDNA with the iScript
1 and GAPDH as control. (B) Twomilligrams of U937 extract was IPed at 4 °C overnight
urs at 4 °C. IPs were washed twice with TNE buffer and kinase buffer. Phosphorylation
ore) as substrate. Following incubation, samples were run on a 4–20% SDS-PAGE, dried
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against GSK-3β or luciferase in the presence or absence of Tat and assayed
for luciferase expression 48 hours post-transfection. Results of such an
experiment are shown in Fig. 6Awhere siLuc or siGSK-3β did not control
much of basal transcription in the Hela TZM-bl cells (lanes 1 and 2).
However, siGSK-3β did signiﬁcantly reduce Tat activated transcription in
these cells (compare lanes3and4). To conﬁrmtheknockdown,whole cell
extract of TZM-bl transfected with siRNAs was run on a 4–20% SDS-PAGE
and Western blotted against GSK-3β and β-actin as control. More than
90% knockdown was observed with siGSK-3β (lower insert, lane 4).
We next asked whether knockdown of GSK-3β could potentially
decreasevirus release fromHIV-1 infectedcells. For thatweused J1-1cells
which are Jurkat derived, contain single copy integrated wild type virus,
and release virus into the supernatant without addition of any external
stimuli (i.e., TNF orHDAC inhibitors).Weperformed the experimentwith
either siLuc as control or siGSK-3β using electroporation. Results of such
an experiment are shown in Fig. 6B, where there was a marked decrease
of RT from cells treated with siGSK-3β at days 2 and 4. Collectively these
data imply that knockdown of GSK-3β in either HeLa or Jurkat (J1-1)
based cells down regulated HIV gene expression and viral production.
Effect of 6BIOder on the dox-dependentHIV-rtTA viruses (Tat/TAR speciﬁcity)
We next asked if the effect of 6BIOder was speciﬁc to Tat function
in HIV-1 expressing cells. For that we obtained two sets of constructsFig. 6. Downregulation of GSK-3β decreases viral transcription in cells. (A) TZM-bl cells w
absence of Tat (1 μg) and assayed for luciferase expression 48 hours post-transfection. To c
TZM-bl transfected with luciferase siRNA (siLuc), and TZM-bl transfected with GSK-3β (siGS
*pb0.01 is related to the comparison between siLuc and siGSK-3β. (B) J1-1 cells were used
electroporated with either siLuc or siGSK-3β (200 nm) and re-plated in complete media. S
treatment was abolished by day 6 (data not shown). *pb0.01 is related to the comparisonfrom the Berkhout lab which have mutation in Tat/TAR sequence.
These viruses can be induced with dox and full particles are recovered
in the supernatant (Verhoef et al., 2001). Brieﬂy, the full-length,
infectious HIV-1 molecular clone pLAI was used for construction of an
HIV-rtTA virus genome, the transcription of which is controlled by
dox. The viral transcriptional elements TAR and Tat were replaced by
the prokaryotic tetO-rtTA elements (Fig. 7A). TAR was inactivated by
mutation of multiple nucleotides in the single-stranded bulge and
loop domains, the binding sites for Tat and cyclin T, respectively. Also,
the inactive TAR motif was inserted in both LTRs to minimize the
chance of reversion to the wild-type virus by a recombination event.
Inactivation of the Tat protein was accomplished by introduction of
the Tyr26Ala point mutation. This single amino acid change resulted
in a severe loss of Tat transcriptional activity and virus replication.
Thus, both LTRs were modiﬁed, and this was done in the wild-type
(W) and mutant (Y) Tat backgrounds, resulting in four HIV-rtTA
constructs: KWK, KYK, SWS, and SYS. In the current study we used the
KWK and KYK sets. The virus variant KWK is most wild type-like
because it maintained the NF-B sites, SP1 sites, and a wild-type Tat
protein, but it has a mutation in TAR. The KYK clone has similar
promoter elements; however the Tat and TAR are both mutated.
These HIV-rtTA replicate in a dox-dependent manner, when trans-
fected into either cell lines or primary PBMCs.
We performed our experiments with the KWK and KYK clones in
primary monocytes that had been differentiated into macrophagesere transfected with siRNA against GSK-3β or luciferase (100 nM) in the presence or
onﬁrm knockdown, 50 μg of whole cell extract of 293T cells (positive control), TZM-bl,
K-3β), were run on a 4–20% SDS-PAGE andWestern blotted against GSK-3β and β-actin.
for electroporation with siLuc or siGSK-3β. Log phase growing cells (5×105/ml) were
upernatants were processed for presence of RT at days 2 and 4. The effect of siGSK-3β
between siLuc and siGSK-3β.
Fig. 7. Effect of BIOder in dox-dependent HIV-1 variants in macrophages. (A) HIV-1 genome and modiﬁcations that were introduced to construct HIV-rtTA. In brief, TAR-Tat
transcriptional axis was replaced by the tetracycline-inducible tetO-rtTA system. Inactivation of TAR and Tat is indicated by crosses through the motifs (Verhoef et al., 2001). (B) The
pLAI chimera plasmids, KWK and KYK (20 μg), were individually transfected (electroporation) into the differentiated macrophages (~4×106) using 250 nM PMA for 3 days. The
culture was maintained with dox (1000 ng/ml) and BIOder (50 nM), and virus replication was monitored by measuring the amount of RT produced in the culture medium at day 10.
No virus replication was observed in the absence of dox, indicating that replication is strictly dependent on the inserted Tet system. (C) Macrophages were treated and transfected as
described above in B. On day 10, cell pellets were lysed in Buffer RLT and RNA extracted by Qiagen's RNeasy kit. RNAwas treated with 0.25 mg/ml DNase I at 37 °C for 1 hour, followed
by heat inactivation at 65 °C for 15 minutes. A total of 30 ng of total RNA was used to generate cDNA with the iScript cDNA Synthesis kit using random primers. PCR was performed
with GAPDH and MCl-1 speciﬁc primers.
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with 20 μg of either KWK or KYK molecular clones and were cultured
without or with dox (1000 ng/ml). Virus production was measured by
RT on culture supernatant samples. Cells treated with dox showed viral
production from both KWK and KYK clones. When cells were treated
with 6BIOder, viral replicationwas inhibited in the KWK (Tat+) and not
KYK (Tat−) clone. We were also interested in determining the effect of
Tat and BIOder treatment on cdk9 responsive genes in primary
macrophages. For this analysis we used MCL-1 as an example, because
we had observed an increase in expression following BIOder treatment
in the monocytic cell line U937. Results in Fig. 7C indicate that MCL-1
expression did not change following treatment with BIOder in the
presence of KWK (Tat+); however a modest decrease (less than 2-fold)
in expression was observed with BIOder treatment in the presence of
KYK (Tat−) clone. These results further reinforce the notion that a
functional Tat is required for the effect of 6BIOder in cells.
6BIOder protects neuronal cultures from the HIV-1 Tat protein
It has been previously shown that GSK-3 inhibitors such as lithium
have neuroprotective effects (Cross et al., 2001). Therefore, we were
interested in determining if 6BIO could protect against Tat induced
death. To this end, rat mixed hippocampal cultures were preincubated
with 6BIO prior to exposure to Tat. Cell death was analyzed 18 hours
after Tat exposure by MTT assay. As expected, Tat treatment reduced
cell viability (Fig. 8A). Importantly, 6BIO was protective against Tat
mediated neurodegeneration, with signiﬁcant neuroprotective effects
at 1.0 and 3.0 μM (pb0.05). There was neurotoxicity observed at 5.0and 10.0 μM of 6BIO, with an LD50 of ~4 μM. 6BIOder had even more
promising results, having a protective effect at 1.0 and 3.0 μM
(pb0.05) (Fig. 8B). Importantly, there was no neurotoxicity observed
at higher concentrations of 6BIOder (5.0 and 10.0 μM). These results
indicate that 6BIO and 6BIOder may be able to protect neuronal
cultures from Tat induced cell death.
Discussion
In this study, we identiﬁed 6BIO as the most potent inhibitor of
Tat-dependent transcription out of 3280 compounds screened. 6BIO, a
synthetic derivative of the natural product, 6-bromoindirubin, is a
potent and speciﬁc GSK-3 inhibitor with an IC50 of 5 nM (Meijer et al.,
2003). 6BIO can also inhibit CDK5/p35, CDK2/cyclin A, and CDK1/
cyclin B complexes with higher IC50s of 0.08, 0.30, and 0.32 μM
respectively (Meijer et al., 2003). Co-crystallization experiments
indicated that 6BIO binds to the ATP pocket of GSK-3β, forming a
van der Waals contact with Leu132, which is replaced by a
phenylalanine in CDK2 and CDK5, providing one explanation for the
preference of 6BIO for GSK-3β (Meijer et al., 2003). 6BIO was found to
be an effective GSK-3 inhibitor both in vitro and in vivo, through the
accumulation of unphosphorylated β-catenin and through modulat-
ing Wnt signaling in Xenopus embryos (Meijer et al., 2003). Along
these lines, there are other GSK-3 inhibitors reported including
lithium, SB-216763, and SB-415286. Lithium is active in the 10–
20 mM range and is known to inhibit other molecules including
polyphosphate-1-phosphate, inositol monophosphatase, casein ki-
nase-II, MAP kinase-activated protein kinase-2, and p38-regulated/
Fig. 8. 6BIO protects neuronal cultures from the HIV-1 Tat protein. Rat mixed
hippocampal cultures were preincubated with various concentrations of (A) 6BIO
(0.05–10 μM) or (B) 6BIOder (0.05–10 μM) for 1 hour at 37 °C prior to an 18-hour
exposure to 500 nM Tat1–72. After 18 hours, cell survival was measured by MTT assay.
Statistical signiﬁcance was determined by ANOVA, followed by Newman–Keuls post
hoc pair-wise comparisons.
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and SB-415286 were originally identiﬁed as GSK-3α inhibitors
through a high throughput screen of the SmithKline Beecham
compound library against rabbit GSK-3α and subsequently were
shown to inhibit human GSK-3 with IC50s of 34 nM and 78 nM
respectively (Coghlan et al., 2000). 6BIO has the lowest IC50 of all
these GSK-3 inhibitors (5 nM) and therefore has the most therapeutic
potential. In addition, in this study we identiﬁed a second generation
6BIO analog, 6BIOder, which has an in vitro IC50 of 0.03 nM and
demonstrated neuronal protectionwith less toxicity than 6BIO. At this
stage it cannot be ruled out that 6BIOder acts through another
unidentiﬁed kinase (i.e., CK1, CLK1 or DYRK from infected cells), or by
inhibition of a collection of various kinases, which jointly results in
selective inhibition of Tat-dependent transcription. Another compli-
cating factor at this point is that cell type difference that was also
observed when 6BIOder inhibited HIV-1 better in U87MG as
compared to monocyte/macrophages cells.
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein
kinase that was originally described as a critical regulator of glycogen
metabolism through the phoshorylation of glycogen synthase (Plyte
et al., 1992). The human GSK-3 family comprises two isoforms, GSK-
3α and GSK-3β, which share 97% sequence identity in their kinase
domain, but differ in their N- and C-terminus regions. GSK-3α/GSK-
3β are implicated in the regulation of glycogen synthesis, the Wnt/β-catenin signaling pathway, PI3K pathway, cell cycle control, tran-
scriptional regulation, and apoptosis (Frame and Cohen, 2001). The
ability of GSK-3α/GSK-3β to regulate this vast array of cellular
processes may be related to its numerous substrates including
glycogen synthase, axin, β-catenin, APC, cyclin D1, c-Jun, c-Myc, C/
EBPα/β, NFATc, RelA and CREB to name just a few (Buss et al., 2004;
Frame and Cohen, 2001). Interestingly, phosphorylation of some
substrates such as glycogen synthase, but not of others such as β-
catenin, by GSK-3 requires a “priming” phosphorylation of the
substrate at a serine residue C-terminal to the GSK-3 phosphorylation
site (Ali et al., 2001). GSK-3β is negatively regulated by PKB/AKT
phosphorylation of Ser9 (Meijer et al., 2004; vanWeeren et al., 1998).
There has been much interest in inhibiting GSK-3β for the treatment
of Alzheimer's disease, and other neurological disorders. This is in
large part due to its proapoptotic effects in neuronal cells (Hetman et
al., 2000). Likewise, GSK-3β inhibitors lithium, SB 216763, and SB
415286 have been shown to protect cerebellar granule neurons from
apoptosis (Cross et al., 2001).
Tat induces GSK-3β activity, which can be reversed by the addition
of the GSK-3β inhibitor lithium (Maggirwar et al., 1999). Furthermore,
the GSK-3β inhibitors lithium and valproic acid (VPA) can protect
against Tat and gp120mediated neurotoxicity (Dou et al., 2003, 2005;
Everall et al., 2002). Rodent and human neurons exposed to culture
ﬂuids from HIV-1-infected monocyte-derived macrophages (MDMs)
were protected from cell death in the presence GSK-3β inhibitors
(lithium, AR-A014418 and 66BIO) (Dou et al., 2005; Nguyen et al.,
2009). Importantly, lithium treatment also resulted in neuronal
protection and neurogenesis in SCID HIV-1 encephalitis (HIVE) mice
(Dou et al., 2005). Sui et al. investigated the role of GSK-3β in NF-kB
regulated neuronal apoptosis (Sui et al., 2006). They found that
neurons exposed to HIVADA-macrophage conditionedmedium (MCM)
displayed decreased NF-kB activity in a Tat-dependent manner. GSK-
3β inhibition through lithium or indirubin treatment blocked NF-kB
inhibition, the suppressive binding of RelA to HDAC3, and neuronal
apoptosis (Sui et al., 2006). Lithium treatment also inhibits HIV-1
replication of both T- and M-tropic viruses in PBMCs as well as TNF
stimulated J1.1 cells (Kumar et al., 2008). Therefore, pharmacological
inhibition of GSK-3β may have implications for the treatment of
HAND as well as in the inhibition of HIV-1 replication in PBMCs.
The role of GSK-3β in HAND is not entirely clear, but it is well
known that GSK-3β is important for both inﬂammation and cell
migration (Jope et al., 2007). An upstream negative regulator of GSK-
3β is PI3K, which limits the release of pro-inﬂammatory cytokines
from monocytes and macrophages (Fukao and Koyasu, 2003).
Likewise, several studies have demonstrated that the inhibition of
GSK-3β is associated with the suppression of inﬂammation. Specif-
ically, in response to stimulation of Toll-like receptors in both
monocytes and peripheral blood mononuclear cells, GSK-3β activity
is necessary for the production of pro-inﬂammatory cytokines, such as
interleukin-6 (IL-6), IL-1β, and tumor necrosis factor (TNF), and
reduction of the anti-inﬂammatory cytokine IL-10 (Martin et al.,
2005). In terms of cell migration, GSK-3β inhibition prevents
extension of lamellipodia in keratinocytes (Koivisto et al., 2004) and
reduces axon elongation rates in neurons (Owen and Gordon-Weeks,
2003). Inhibition of GSK-3 through 6BIO treatment or RNAi also
prevented migration of epithelial cells (Farooqui et al., 2006). Thus it
would be expected that GSK-3β inhibition through 6BIO treatment
would have a profound effect on both inﬂammatory responses and
cellular migration in response to inﬂammatory signals.
Our studies demonstrate for the ﬁrst time the ability of 6BIO to
inhibit Tat-dependent transcription. GSK-3β regulates a number of
transcription factors and co-factors including β-catenin, c-Jun, c-Myc,
C/EBPα/β, NFATc, RelA and CREB (Buss et al., 2004; Frame and Cohen,
2001), most of which have also been implicated in Tat mediated
transcription (Rohr et al., 2003). Studies are underway to identify
factor occupancy changes at LTR following 6BIO treatment to
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transcription. Of particular interest is the β-catenin/T-cell factor-4
(TCF-4) pathway, which has important connections in neuronal
development and multiple neurological disorders (Cerpa et al., 2009).
Interestingly, TCF-4 has been shown to inhibit HIV-1 transcription
(Carroll-Anzinger et al., 2007; Rossi et al., 2006; Wortman et al.,
2002). While initial studies indicated that the TCF-4 mediated
inhibition of HIV-1 transcription was β-catenin independent (Wort-
man et al., 2002), later studies utilizing a TCF-4 dominant negative
construct, which is mutated in the β-catenin binding site, suggest that
β-catenin is important for the observed effects (Carroll-Anzinger et
al., 2007). β-Catenin binding to TCF-4 results in the release of TCF-4
repressors, such as transducin-like enhancer, allowing the TCF-4/β-
catenin complex to bind to DNA and regulate transcription. β-Catenin
proteasomal degradation is induced by GSK-3β-dependent phosphor-
ylation (Amit et al., 2002; Rubinfeld et al., 1996) and thus stabilization
of β-catenin would be expected following 6BIO treatment, as shown
in (Polychronopoulos et al., 2004).
In addition to the β-catenin/TCF-4 pathway, the NF-kB pathway is
highly regulated by GSK-3β. Expression of a constitutively active GSK-
3β mutant (S9A) and inhibition of the PI3K pathway (thus allowing
GSK-3β to remain active) result in astrocyte apoptosis (Rao et al.,
2004). This may be due at least in part to the inhibition of the NF-κB
pathway (Bournat et al., 2000; Rao et al., 2004; Sanchez et al., 2003).
In the presence of constitutively active GSK-3β, inhibition of NF-κB
was observed alongwith stabilization of the NF-κB-inhibitory protein,
IκBα and down-regulation of IκB kinase (IKK) activity. GSK-3β can
directly inhibit NF-kB through phosphorylation of RelA at serine 468,
resulting in an inactivated form of NF-kB (Buss et al., 2004). However,
the reverse has also been demonstrated, where GSK-3βwas shown to
be essential for NF-κB mediated apoptosis in response to TNF-α
treatment (Hoeﬂich et al., 2000). Thus the inﬂuence of GSK-3β on NF-
κB activity may be stimulus, cell type and/or promoter speciﬁc.
Conclusions
Our studies indicated that 6BIO and 6BIOder can inhibit both Tat-
dependent transcription and neuronal cell death. The combined anti-
proliferative and anti-inﬂammatory properties of 6BIO and 6BIOder
make them an attractive treatment towards the control of HAND.
While the mechanism of neuroprotection is currently unknown and
likely to be multifaceted; it is clear that 6BIO and 6BIOder have great
potential to be used as a supplement to current HIV-1 therapies.
Materials and methods
Cell culture and reagents
TZM-bl, U87MG, and 293T Cells were grown and cultured to
conﬂuency in Dulbecco's modiﬁed Eagle's medium supplemented
with 10% heat-inactivated FBS, 1% L-glutamine, and 1% streptomycin/
penicillin (Gibco/BRL, Gaithersburg, MD, USA). The latently infected
promonocytic U1 cell line and the uninfected corresponding U937 cell
line, as well as infected J1.1, ACH2 and their uninfected counterparts
Jurkat and CEM (12D7) cells were cultured up to 1×105 cells per ml
(early log phase of growth) in RPMI-1640 medium supplemented
with 10% heat-inactivated FBS, 1% L-glutamine, and 1% streptomycin/
penicillin. ACH2, J1-1 contain a single integrated copy of HIV-1
genome, whereas U1 cells harbor two copies (one wild type and one
mutant) of the viral genome in parental U973 cells. All cells were
incubated at 37 °C and 5% CO2. The reporter T-cell lines JLTRG and
TiGR were maintained at an average cell density of 0.5×106 cells/ml
in RPMI 1640 (Mediatech, Herndon, VA, USA) supplemented with
2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and
10% heat-inactivated fetal bovine serum (FBS; HyClone, Logan, UT,
USA) (Jones et al., 2007). TiGR cells were derived by retroviraltransduction of JLTRG cells with a retroviral MSCV-LTR-driven Tat-
expression vector.
PBMCs used to generate infectious viral supernatants were
isolated from the blood of healthy donors by Ficoll-Paque™ density
gradient centrifugation (Amersham 6BIOsciences, Uppsala, Sweden)
and were cultured in RPMI 1640 supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/
ml streptomycin. PBMCs were initially PHA/interleukin-2 stimulated
and infected with HIV-1 89.6 strain 4 days following stimulation. All
antibodies were purchased from BD Pharmingen (San Diego, CA,
USA). PHA-L was obtained from Sigma (St. Louis, MO, USA), and IL-2
was purchased from 6BIOsource International (Camarillo, CA, USA).
384-Well plate-based ﬂuorometry assays
All plate-based experiments were performed in 384-well optical
bottom black wall plates (Nalgen Nunc International, Rochester, NY,
USA) and designed to obtain a ﬁnal cell density of 1×106 cells/ml in a
ﬁnal volume of 90 μl phenol red-free RPMI 1640 per well. This optimal
number was obtained by titrating TiGR cells over a range of cell
numbers per well (1×103 to 1×106 cell/well). The phenol red-free
RPMI 1640 used in all experiments was supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2% heat-
inactivated FBS. Analysis was performed using a Synergy™ HT Multi-
Detection Microplate Reader (6BIO-Tek Instruments, Winooski, VT,
USA), equipped with the following ﬁlter set: excitation, 488/20 nm;
emission, 525/20 nm.
To determine the Z′-factor, JLTRG or TiGR cells were adjusted to a
cell density of 2×106 cells/ml in phenol red-free RPMI 1640
supplemented with 2% FBS, of which 50 μl was loaded per well.
Compounds/inhibitors
The indirubin derivatives used in this study were 1: 2-{[[2-(5-
bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino](oxo)acetyl]
amino}benzoic acid, 2: N′~1~,N′~4~-bis(5-methyl-2-oxo-1,2-dihydro-
3H-indol-3-ylidene)terephthalohydrazide, 3: 5-bromo-3-({2-[(2-oxo-
1,2-dihydro-3H-indol-3-ylidene)amino]phenyl}imino)-1,3-dihydro-
2H-indol-2-one, 4: 4-bromo-5-methyl-1H-indole-2,3-dione 3-oxime, 5:
4-bromo-5-methyl-1H-indole-2,3-dione 3-(N-phenylsemicarbazone),
6: 6-bromo-5-methyl-1H-indole-2,3-dione 3-[(6-bromo-5-methyl-2-
oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazone], 7: N′-(5-bromo-7-
methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-chlorobenzohydra-
zide, 8: N′-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-chlor-
obenzohydrazide, 9: 5,7-dibromo-1H-indole-2,3-dione 3-
(phenylhydrazone), 10: 5,7-dibromo-1H-indole-2,3-dione 3-oxime,
11: 2-chloro-N′-(5,7-dibromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)
benzohydrazide, 12: 2-bromo-N′-(5,7-dibromo-2-oxo-1,2-dihydro-3H-
indol-3-ylidene)benzohydrazide, 13: N′-(4-bromo-5-methyl-2-oxo-1,2-
dihydro-3H-indol-3-ylidene)-3,5-dihydroxybenzohydrazide, 14: N′-(5-
bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-methyl-3-furohydra-
zide, 15: N-(1-{[2-(5-ﬂuoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)
hydrazino]carbonyl}-2-phenylvinyl)benzamide, 16: N′-(5-bromo-2-
oxo-1,2-dihydro-3H-indol-3-ylidene)-2,4-dichlorobenzohydrazide, 17:
4-bromo-5-methyl-1H-indole-2,3-dione 3-(phenylhydrazone), 18: 6-
chloro-7-methyl-1H-indole-2,3-dione 3-oxime, 19: 4-chloro-7-methyl-
1H-indole-2,3-dione 3-oxime, 20: 3-[(1H-indazol-5-ylamino)methy-
lene]-1,3-dihydro-2H-indol-2-one, 21: 2-(5-bromo-2-methyl-1H-indol-
3-yl)-N′-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)acetohydrazide, 22:
N′-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)-3-phenyl-1H-pyrazole-5-
carbohydrazide, 23: N′-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-yli-
dene)-3-phenyl-1Hpyrazole-5-carbohydrazide, 24: N′-(5,7-dibromo-
2-oxo-1,2-dihydro-3H-indol-3-ylidene)-3-phenyl-1Hpyrazole-5-carbo-
hydrazide, 25: N-[1-{[2-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-yli-
dene)hydrazino]carbonyl}-2-(3,4-dimethoxyphenyl)vinyl]benzamide,
26: N-[1-{[2-(5-bromo-7-methyl-2-oxo-1,2-dihydro-3H-indol-3-
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mide, 27: 3-(4-methoxyphenyl)-N′-(2-oxo-1,2-dihydro-3H-indol-3-yli-
dene)-1Hpyrazole-5-carbohydrazide, 28: N′-(5-bromo-2-oxo-1,2-
dihydro-3H-indol-3-ylidene)-3-(4-methoxyphenyl)-1H-pyrazole-5-
carbohydrazide, 29: 3-(4-ethoxyphenyl)-4-methyl-N′-(2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene)-1H-pyrazole-5-carbohydrazide, 30: 3-(2-
naphthyl)-N′-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)-1H-pyrazole-5-
Carbohydrazide, 31: N-(2-{[2-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-
ylidene)hydrazino]carbonyl}phenyl)benzamide, 32: N′-(5-bromo-2-
oxo-1,2-dihydro-3H-indol-3-ylidene)-3-methyl-1Hpyrazole-5-carbohy-
drazide, 33: 5-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,4-
imidazolidinedione, 34: 5-bromo-5′-chloro-3,3′-biindole-2,2′(1H,1′H)-
dione, 35: 5-chloro-3,3′-biindole-2,2′(1H,1′H)-dione, 36: 5-ﬂuoro-3,3′-
biindole-2,2′(1H,1′H)-dione, 37: 5-bromo-7-methyl-3,3′-biindole-2,2′
(1H,1′H)-dione, 38: 6-chloro-7-methyl-3,3′-biindole-2,2′(1H,1′H)-
dione. All inhibitors were prepared in 10 mM stock solution dissolved
in DMSO.
Derivative screening and luciferase assay
TZM-bl cells were transfected with pc-Tat (1 μg) or silencing RNA
(100 nM) against GSK-3β (Cell Signaling Technology, Danvers, MA,
USA) or luciferase (Dharmacon, Lafayette, CO, USA) using the
AttracteneLipofectamine reagent (InvitrogenQiagen, Chatsworth, CA,
USA) according to themanufacturer's instructions. TZM-bl cells contain
an integrated copy of the ﬁreﬂy luciferase gene under the control of the
HIV-1 promoter (obtained through the NIH AIDS Research and
Reference Reagent Program). The next day, cells were treated with
DMSO or the indicated compound at 1 μM. Forty-eight hours post drug
treatment, luciferase activity of the ﬁreﬂy luciferasewasmeasuredwith
the BrightGlo Luciferase Assay (Promega, Madison, WI, USA) and
luminescence was read from a 96-well plate on an EG&G Berthold
luminometeR (Berthold Technologies, Oak Ridge, TN, USA).
MTT assay
Fifty thousand cells were plated per well in a 96-well plate and the
next day cells were treated with 1 μM compound or DMSO. Forty-
eight hours later, 10 μl MTT reagent (5 mg/ml)was added to eachwell
and plates incubated at 37 °C for 2 hours. Next, 100 μl of DMSO was
added to each well and the plate was shaken for 15 minutes at room
temperature. The assay was read at 570 nM using a SpectraMax 340
plate reader (Molecular Devices, Sunnyvale, CA, USA).
Protein extracts and immunoblotting
Whole cell extracts from were prepared. Cells were collected,
washed once with PBS and pelleted. Cells were lysed in a buffer
containing Tris–HCl pH 7.5, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40,
50 mM NaF, 0.2 mM Na3VO4, 1 mM DTT and one tablet complete
protease inhibitor cocktail per 50 ml. Lysis was performed under ice-
cold conditions, incubated on ice for 30 minutes and spun at 4 °C for
5 minutes at 14,000 rpm. The protein concentration for each prepa-
ration was determined with a Bio-Rad protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA). Cell extracts were resolved by SDS
PAGE on a 4–20% tris–glycine gel (Invitrogen, Carlsbad, CA, USA).
Proteins were transferred to polyvinylidene diﬂuoride microporous
membranes using the iBlot dry blotting system as described by the
manufacturer (Invitrogen). Membranes were blockedwith Dulbecco's
phosphate-buffered saline (PBS) 0.1% Tween-20+3% BSA. Primary
antibody against speciﬁed proteins was incubated with the mem-
brane in blocking solution overnight at 4 °C. Antibodies against GSK-
3β (1V001) and β-actin (C-11) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Membranes were washed twice
with PBS+0.1% Tween-20 and incubated with HRP-conjugated
secondary antibody for 1 hour in blocking solution. Presence ofsecondary antibody was detected by SuperSignal West Dura Extended
Duration Substrate (Pierce, Rockford, IL, USA). Luminescence was
visualized on a Kodak 1D image station (Carestream Health,
Rochester, NY, USA).
RT assay
For RT assays, viral supernatants (10 μl) were incubated in a 96-
well plate with RT reaction mixture containing 1× RT buffer (50 mM
Tris–HCl, 1 mM DTT, 5 mM MgCl2, 20 mM KCl), 0.1% Triton, poly(A)
(10–2 U), poly(dT) (10–2 U) and [3H]TTP. The mixture was incubated
overnight at 37 °C and 5 μl of the reaction mix was spotted on a DEAE
Filter mat paper (PerkinElmer, Shelton, CT, USA) washed four times
with 5% Na2HPO4 and three times with water, and then dried
completely. RT activity was measured in a Betaplate counter (Wallac,
Gaithersburg, MD).
RT-PCR and primers
For RNA analysis of CDK9/cyclin T-dependent genes (Mcl-1, IL-8,
cyclin D1) following drug treatments, total RNA was isolated from
U937 and U87MG cells using Trizol (Invitrogen) according to the
manufacturer's protocol. A total of 1 μg of RNA from the RNA fraction
was treated with 0.25 mg/ml DNase I for 60 minutes, followed by heat
inactivation at 65 °C for 15 minutes. A total of 1 μg of total RNA was
used to generate cDNA with the iScript cDNA Synthesis kit (BIO-Rad)
using oligo-dT reverse primers.
Immunoprecipitation and in vitro kinase assay
For immunoprecipitation (IP) 2 mg of extract from 6BIO or
6BIOder-treated (1, 10 μM) U937 cells was immunoprecipitated at
4 °C overnight with GSK-3β antibody. The next day complexes were
precipitated with A/G beads (Calbiochem) for 2 hours at 4 °C. IPs were
washed twice with appropriate TNE buffer and kinase buffer. Reaction
mixtures (20 μl) contained ﬁnal concentrations: 40 mM β-glycero-
phosphate pH 7.4, 7.5 mM MgCl2, 7.5 mM EGTA, 5% glycerol, [γ-32P]
ATP (0.2 mM, 1 μCi), 50 mMNaF, 1 mM orthovanadate, and 0.1% (v/v)
β-mercaptoethanol. Phosphorylation reactions were performed with
IP material and 200 ng of glycogen synthase peptide 2 (Millipore) as
substrate in TTK kinase buffer containing 50 mM HEPES (pH 7.9),
10 mMMgCl2, 6 mM EGTA, and 2.5 mM dithiothreitol. Reactions were
incubated at 37 °C for 1 hour and stopped by the addition of 1 volume
of Laemmli sample buffer containing 5% β-mercaptoethanol and ran
on a 4–20% SDS-PAGE. Gels were subjected to autoradiography and
quantitation using a Molecular Dynamics PhosphorImager software
(Amersham 6BIOsciences, Piscataway, NJ, USA).
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